Table 1.

Characteristics of included studies.

Author	Participants	Baseline weight	Type of intervention	Duration of follow-up (week)	Antipsychotic	Design	N at baseline
Alexopoulos et al. (51)	Major depression	NA	Drug versus placebo in maintenance phase	24	Risperidone	Randomized	63
	Mean age 63.4
	44% male
Beasley et al. (23)	Schizophrenia/schizoaffective	NA	Drug versus placebo in maintenance phase	52	Olanzapine	Randomized	326
	Mean age 35.7
	53% male
Berwaerst et al. (36)	Bipolar	78 kg	Drug versus placebo in maintenance phase	170	Risperidone	Randomized	300
	Mean age 40
	45% male
Brunner et al. (41)	Major depression	83.1 kg	Drug versus placebo in maintenance phase	27	Olanzapine	Randomized	444
	Mean age 44
	33.1% male
Calabrese et al. (37)	Bipolar	89.2	Drug versus placebo in maintenance phase	52	Aripiprazole	Randomized	266
	Mean age 40.6
	42.5% male
Carlson et al. (63)	Bipolar	86.6	Drug versus placebo in maintenance phase	52	Aripiprazole	Randomized	351
	Mean age 39
	35% male
Chen et al. (24)	Schizophrenia	66.0	Dose reduction versus maintenance	52	Quetiapine	Randomized	178
	Mean age 24.2
	45% male
Chen et al. (69)	Schizophrenia/bipolar	98.5	Switch to aripiprazole	52	Second generation antipsychotic	No control group	24
	Mean age 45.3
	45,8% male
Casey et al. (26)	Schizophrenia	90.2	Switch to aripiprazole	8		Randomized	311
	Mean age 39
	70% male
Cooper et al. (75)	Schizophrenia	76.7	Drug versus placebo in maintenance phase	26	Zotepine	Randomized	121
	mean age 42.3
	68% male
Durgham et al. (53)	Schizophrenia	75.3	Drug versus placebo in maintenance phase	72	Cariprazine	Randomized	200
	Mean age 38
	66% male
Fleischhacker et al. (55)	Schizophrenia	82.9	Drug versus placebo in maintenance phase	52	Brexpiprazole	Randomized	202
	Mean age 39.7
	61% male
Flint et al. (32)	Major depression	77.3	Drug versus placebo in maintenance phase	36	Olanzapine	Randomized	126
	Mean age 55.3
	38.1% male
Fu et al. (46)	Schizoaffective	78.6	Drug versus placebo in maintenance phase	60	Paliperidone	Randomized	334
	Mean age 38.6
	50.6% male
Ganguli et al. (76)	Schizophrenia	47.8	Switch to aripiprazole	8		No control group	33
	NA
	28% male
Graff-Guerrero et al. (59)	Schizophrenia	83.8	Dose reduction	Variable	Olanzapine/Risperidone	No control group	35
	Mean age 60
	74% male
Hwang et al. (49)	Schizophrenia	66 kg	Switch to aripiprazole	8	Aripiprazole	No control group	79
	Mean age 39
	40.6% male
Ishigooka et al. (66)	Schizophrenia	65.5	Switch to brexpiprazole	56	Brexpiprazole	No control group	47
	Mean age 49
	51% male
Kane et al. (43)	Schizophrenia	77,7 kg	Drug versus placebo in maintenance phase	24 weeks	Olanzapine	Randomized	466
	Mean age 39 years
	66% male
Kane et al. (44)	Schizophrenia	76,5	Drug versus placebo in maintenance phase	26	Asenapine	Randomized	386
	Mean age 39
	57.4% male
Kane et al. (57)	Schizophrenia	83,8	Drug versus placebo in maintenance phase	52	Aripiprazole	Randomized	403
	Mean age 40.9
	59.6% male
Keck et al. (50)	Bipolar	85.7 kg	Drug versus placebo in maintenance phase	74	Aripiprazole	Randomized	151
	Mean age 39.6
	33% male
Kim et al. (28)	Schizophrenia	104.1	Switch to aripiprazole	16	Aripiprazole	No control group	15
	Mean age 34
	60% male
Kim et al. (30)	Schizophrenia	67 kg	Switch to aripiprazole	26		No control group	61
	Mean age 30.8
	44.3% male
Kramer et al. (42)	Schizophrenia	79,5	Drug versus placebo in maintenance phase	52	Paliperidone	Randomized	113
	Mean age 38.2
	59% male
Liebowitz et al. (71)	Major depression	83 kg	Drug versus placebo in maintenance phase	52	Quetiapine	Randomized	776
	Mean age 44.6 years
	34% male
Macfadden et al. (38)	Bipolar	70	Drug versus placebo in maintenance phase	52	Risperidone	Randomized	124
	Mean age 38.7
	71.8% male
Marcus et al. (70)	Bipolar	81	Drug versus placebo in maintenance phase	52	Aripiprazole	Randomized	337
	39 years
	45.1% male
Newcomer et al. (72)	Schizophrenia/schizoaffective	92	Switch to aripiprazole	16	Olanzapine	Randomized	173
	Mean age 39.2
	64.2% male
Ozawa et al. (73)	Schizophrenia	57	Dose reduction versus maintenance	52	Olanzapine/Risperidone	Randomized	35
	Mean age 64
	66% male
Pae et al. (29)	Schizophrenia	66.4 kg	Switch to aripiprazole	12		Randomized	77
	Mean age 36.4
	42,8% male
Peuskens et al. (54)	Schizophrenia	70	Drug versus placebo in maintenance phase	24	Quetiapine	Randomized	197
	Mean age 36
	60% male
Pigott et al. (35)	Schizophrenia	75	Drug versus placebo in maintenance phase	26	Aripiprazole	Randomized	310
	Mean age 42 years
	56.1% male
Quiroz et al. (33)	Bipolar	75.1 kg	Drug versus placebo in maintenance phase	96	Risperidone	Randomized	303
	Mean age 39
	51% male
Rapaport et al. (45)	Major depression	NA	Drug versus placebo in maintenance phase	24	Risperidone	Randomized	243
	Mean age 48.3
	36,2% male
Rouillon et al. (56)	Schizophrenia	76.4	Dose reduction versus maintenance	24	Olanzapine	Randomized	97
	Mean age 39.3
	68.3% male
Ryckman et al. (67)	Schizophrenia	80.3 kg	Switch to aripiprazole	12	Aripiprazole	No control group	400
	Mean age 41
	56% male
Rui et al. (68)	Schizophrenia	63.4	Drug versus placebo in maintenance phase	52	Paliperidone	Randomized	136
	Mean age 31
	41% male
Schorr et al. (61)	Schizophrenia	97.0	Switch to aripiprazole	12		No control group	53
	Mean age 35
	60% male
Spurling et al. (27)	Schizophrenia/bipolar	NA	Switch to aripiprazole	24		No control group	23
	Mean age 45
	67% male
Stroup et al. (77)	Schizophrenia/schizoaffective	103	Switch to aripiprazole	24	Olanzapine/Risperidone/Quetiapine	Randomized	205
	Mean age 41
	63.7% male
Suppes et al. (64)	Bipolar	86.4	Drug versus placebo in maintenance phase	104	Quetiapine	Randomized	628
	Mean age 40.1
	47.5% male
Suzuki et al. (60)	Schizophrenia	62.5	Switch to aripiprazole	Variable		No control group	19
	NA
	NA
Takeuchi (34)	Schizophrenia	68.8	Dose reduction versus maintenance	28	Olanzapine/Risperidone	Randomized	61
	Mean age 39
	60% male
Takeuchi et al. (31)	Schizophrenia	63.1	Switch to aripiprazole	52		No control group	32
	Mean age 27
	56.2% male
Tohen et al. (39)	Bipolar	NA	Drug versus placebo in maintenance phase	72	Olanzapine	Randomized	99
	Mean age 41.2
	48.3% male
Tohen et al. (48)	Bipolar		Drug versus placebo in maintenance phase	48	Olanzapine	Randomized	356
	Mean age 40.4
	39% male
Tsuboi et al. (47)	Schizophrenia	60.2 kg	Dose reduction versus maintenance	52	Olanzapine/Risperidone	Randomized	68
	Mean age 55.4
	60.3% male
Wang et al. (58)	Schizophrenia		Dose reduction versus maintenance	52	Risperidone	Randomized	404
	Mean age 32.6	NA
	46% male
Woo et al. (74)	Bipolar	70.9	Switch to aripiprazole	24	Aripiprazole	No control group	77
	Mean age 36
	38% male
Weisler et al. (25)	Bipolar	71.6	Drug versus placebo in maintenance phase	104	Quetiapine	No control group	808
	Mean age 39.5
	46.7% male
Weiden et al. (40)	Schizophrenia	75.4 kg	Drug versus placebo in maintenance phase	24	Iloperidone	Randomized	303
	Mean age 38,3
	58.7% male
Weiss et al. (65)	Schizophrenia	Na	Drug versus placebo in maintenance phase	24	Brexpiprazole	Randomized	202
	NA
	NA
Young et al. (52)	Bipolar	78.8	Drug versus placebo in maintenance phase	52	Quetiapine	Randomized	584
	Mean age 40.3
	41.2% male
Yatham et al. (62)	Bipolar	80.3	Drug versus placebo in maintenance phase	52	Aripiprazole	Randomized	105
	Mean age 37.9
	50% male